quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·25d
PRRelease
Enanta Pharmaceuticals Inc. logo

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)

ENTA· Enanta Pharmaceuticals Inc.
Health Care
Original source

Companies

  • ENTA
    Enanta Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 26UpdateRodman & Renshaw$20.00
  • Nov 14UpdateAnalyst-
  • Oct 1UpdateJefferies$20.00
  • Jul 28UpdateH.C. Wainwright$20.00
  • Aug 9UpdateJP Morgan$14.00
  • Aug 8UpdateJefferies$18.00

Related

  • PR11d
    Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
  • PR17d
    Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
  • SEC28d
    Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.
  • ANALYST28d
    Rodman & Renshaw initiated coverage on Enanta Pharmaceuticals with a new price target
  • SEC28d
    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Other Events
  • INSIDER41d
    SEC Form 4 filed by Director Vance Terry
  • INSIDER41d
    SEC Form 4 filed by Director Russell Lesley
  • INSIDER41d
    SEC Form 4 filed by Director Peterson Kristine
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022